Quantitative signal detection using spontaneous ADR reporting

Pharmacoepidemiology and Drug Safety - Tập 18 Số 6 - Trang 427-436 - 2009
Andrew Bate1,2, Stephen Evans3
1Department of Information Systems and Computing, Brunel University, West London, UK
2WHO Collaborating Centre for International Drug Monitoring, Uppsala, Sweden
3London School of Hygiene and Tropical Medicine, Keppel Street, University of London, UK

Tóm tắt

AbstractQuantitative methods are increasingly used to analyse spontaneous reports. We describe the core concepts behind the most common methods, the proportional reporting ratio (PRR), reporting odds ratio (ROR), information component (IC) and empirical Bayes geometric mean (EBGM). We discuss the role of Bayesian shrinkage in screening spontaneous reports, the importance of changes over time in screening the properties of the measures. Additionally we discuss three major areas of controversy and ongoing research: stratification, method evaluation and implementation. Finally we give some suggestions as to where emerging research is likely to lead. Copyright © 2009 John Wiley & Sons, Ltd.

Từ khóa


Tài liệu tham khảo

10.1111/j.1365-2125.1988.tb03357.x

10.2165/00002018-199410020-00001

10.1002/sim.4780071004

10.1002/sim.4780122414

10.1016/S0140-6736(97)26018-6

Finney DJ, 1974, Systematic signalling of adverse reactions to drugs, Methods Inf Med, 13, 1, 10.1055/s-0038-1636131

10.1592/phco.24.13.1122.38098

10.2165/00002018-200023060-00004

10.1007/s002280050498

10.1002/pds.677

10.1046/j.1365-2125.1997.00615.x

10.1002/pds.668

10.1007/s002280050466

10.2307/2686093

10.1002/pds.771

10.2165/00002018-200225060-00001

10.1002/0470853093.ch20

10.1002/pds.894

10.1002/pds.615

10.1002/pds.849

10.1002/pds.848

10.1002/sim.1157

Mantel N, 1959, Statistical aspects of the analysis of data from retrospective studies of disease, J Nat Cancer Inst, 719

10.1002/sim.2473

10.2165/00002018-200831110-00008

10.2165/00002018-200326050-00005

10.2165/00002018-200831110-00009

10.2165/00002018-200831080-00003

10.1007/s00228-004-0834-0

10.2165/00002018-200427100-00004

10.1109/TITB.2005.855566A

10.1002/sim.2035

10.1136/bmj.305.6856.748-a

10.1136/bmj.305.6860.1019-a

10.1111/j.1572-0241.2001.03927.x

10.1016/S0140-6736(05)17865-9

10.1136/bmj.322.7296.1207

10.1080/10245330410001714220

ZhouW PoolV DeStefanoF et al.A potential signal of Bell's palsy after parenteral inactivated influenza vaccines: reports to the Vaccine Adverse Event Reporting System (VAERS)—United States. 1991–2001.Pharmacoepidemiol Drug Saf2004;13:505–510.

10.1016/S0264-410X(01)00237-7

10.2165/00002018-200427120-00003

10.1002/pds.684

Bate A, 2003, Clinical Pharmacology

10.1002/pds.1001

10.1002/pds.1002

10.1002/(SICI)1099-1557(199904)8:1 <S15::AID-PDS402>3.0.CO;2-B

10.1145/502512.502526

Evans SJW, 2004, Stephens' Detection of New Adverse Drug Reactions, 301

10.2165/00002018-200225060-00005

10.2165/00002018-200225060-00009

10.1016/S1386-5056(00)00062-9

10.2165/00002018-200528010-00002

10.1142/S0129065705000219

10.1016/0140-6736(90)91669-2

10.1345/aph.19235

10.2165/00002018-200225060-00011

10.1002/(SICI)1099-1557(199912)8:7<535::AID-PDS456>3.0.CO;2-D

Amery WK, 1994, Post‐marketing drug safety management: a pharmaceutical industry perspective, Int J Risk Saf Med, 5, 67

10.1007/s00228-002-0484-z

10.1007/s002280000215

10.1016/S0167-9473(99)00114-0

10.1002/sim.3247

Bate A, 2004, Pattern detection for celecoxib and rofecoxib in the WHO Database (Abstract), Pharmacoepidemiol Drug Saf, 323

10.1007/s10618-006-0052-8

10.2165/00002018-200225060-00006

Anonymous Appendix 3: Pilot Data Report.2003 National Patient Safety Agency: London.http://www.npsa.nhs.uk/admin/publications/docs/businessplan.pdf

10.1002/pds.1509

NorénGN BateA HopstadiusJ et al.Temporal pattern discovery for trends and transient effects: its application to patient records In Fourteenth ACM SIGKDD International Conference on Knowledge Discovery and Data Mining Las Vegas 2008.

Bate A, 2004, Knowledge finding in IMS Disease Analyser Mediplus UK database—effective data mining in longitudinal patient safety data, Drug Saf, 27, 917

10.1046/j.0306-5251.2001.01501.x

10.1177/009286159603000216

10.2165/00002018-200326100-00005

10.1002/pds.773